← Back to headlines
Gilead Sciences Outlook Cut Sharply on IPR&D and Financing Costs
Gilead Sciences, Inc. (GILD) has seen its outlook cut sharply due to significant $11.5 billion IPR&D (In-Process Research and Development) and financing costs, impacting its financial projections.
11 May, 20:01 — 11 May, 20:01
Sources
Showing 1 of 1 sources
